Management discusses expert clinical perspectives on CAN-2409 Phase 3 prostate cancer data on a conference call to be held on June 3 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Receives FDA RMAT Designation for CAN-2409
- Candel Therapeutics receives FDA RMAT designation to CAN-2409
- Candel Therapeutics to host investor call on CAN-2409 Phase 3 data
- Candel Therapeutics Unveils Promising Phase 3 Trial Results
- Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics